Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

Panacea Biotec Limited

Anthem Biosciences is involved in the chemistry and biology sectors, offering services from gene design to manufacturing and commercialization.

Anthem Biosciences

Panacea Biotec is an innovation driven company focused on research and development, manufacturing, sales, distribution, and marketing of nutrition, vaccines, and pharmaceuticals.

Metric
Company Name	Panacea Biotec Limited	Anthem Biosciences
Symbol	PANACEABIO
MSH ID	COM:PANACEABIOTEC	COM:ANTHEMBIO
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	IN	IN
Stage
Employee Count	1.79K
Website	panaceabiotec.com	anthembio.com
LinkedIn
Founders

Metric
Market Cap	101.56M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	66.02M
Revenue (LTM)
Revenue (NTM)
Gross Profit	16.86M
EBITDA	-2.37M
Operating Income	-6.70M
Net Income	-138.13K
EPS	-0.00
Diluted EPS	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.48
Operating Profit Margin	-0.08
EBITDA Margin	-0.04
Net Profit Margin	-0.00
Return on Equity	-0.00
Return on Assets
Return on Capital Employed

COM:PANACEABIOTEC

Panacea Biotec

Last Close

410.00

25/11 09:40

Market Cap

8.60B

Beta: -

Volume Today

219.14K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	105.92
P/B Ratio	1.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.95
EV Multiple	174.46

Metric
Days Sales Outstanding	55.39
Days Payables Outstanding	291.99
Days Inventory Outstanding	200.38
Operating Cycle	239.94
Cash Conversion Cycle	66.88
Asset Turnover	0.45

Metric
Operating Cash Flow	674.13K
Free Cash Flow	-8.50M
Cash Flow to Debt	3.56
Operating Cash Flow/Sales	0.14
Free Cash Flow Yield

Metric
Cash & Equivalents	16.47M
Accounts Receivable	349.46K
Inventory	21.01M
Goodwill
Debt to Capitalization	0.02
Debt to Assets	0.02
Current Ratio	1.61
Quick Ratio	0.99

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue